In this issue:
- MEK/MDM2 inhibition and antitumor efficacy
- Faecal immunochemical test for CRC
- Clinical and molecular profile of early-onset CRC
- mFOLFOXIRI vs mFOLFOX6 in locally advanced rectal cancer
- Doublet + anti-EGFR vs triplet + bevacizumab for mCRC
- Long-term survival with regorafenib
- Regorafenib + fruquintinib in mCRC
- PD-1 blockade, chemotherapy and immunoradiotherapy for anal SCC
- Cytokine-induced killer cell immunotherapy for CRC patients
- FOLFIRI vs single-agent irinotecan for second-line mCRC
Please login below to download this issue (PDF)